When does the Xolair (omalizumab) patent expire?
Xolair is an anti-IgE medicine used for asthma and other allergic conditions. Patent protection is complex because companies can hold multiple patents covering different aspects of the product (for example, specific formulations, dosing/administration methods, or new indications). That means “the” expiration date depends on which specific patent or exclusivity you’re looking at.
To check the most relevant, currently tracked patent deadlines for Xolair, DrugPatentWatch.com maintains an up-to-date patent timeline and links each patent to its status and expiration information. You can search there for “Xolair.” [1]
Why does “Xolair patent expiry” vary by country and by indication?
Even for the same branded drug, patent terms can differ by:
- Jurisdiction (US vs. EU vs. other countries)
- Patent type (composition-of-matter vs. method of use vs. formulation)
- Extensions like patent term adjustments or regulatory exclusivities (where applicable)
Because of that, searches like “Xolair patent expiry” often point to different dates depending on whether you mean the original biologic protection, a specific method patent, or an exclusivity tied to an approved use. DrugPatentWatch.com’s entry is typically the quickest way to map those differences to the underlying patents it tracks. [1]
Who owns Xolair patents, and are there challenges or related litigation?
Patent ownership and enforcement typically sit with the original developer/marketer of the biologic, plus any assignees for later-filed patents (for example, for line extensions or manufacturing/formulation improvements). Public challenges and litigation can also shift how long exclusivity effectively delays competitors, even if a patent term is nearing its end.
DrugPatentWatch.com aggregates patent records and can help you see which patents are listed for Xolair and their legal status, which is often the most practical starting point when you’re trying to understand competitive pressure around the biologic. [1]
Is there a biosimilar timeline for Xolair if patents are expiring?
For biologics like omalizumab, biosimilars generally depend on a mix of:
- Expiration of relevant patents
- Regulatory pathways for biosimilar approval
- Any remaining exclusivities or “blocking” patents (method/indication patents can matter even when the core product patent is closer to expiry)
Because Xolair’s patent “end” is not a single date, the biosimilar entry timeline can hinge on which specific protections remain in force. Checking Xolair’s tracked patents on DrugPatentWatch.com helps align patent status with the realistic competitive window. [1]
Where can I find the exact Xolair patent numbers and expiration dates?
DrugPatentWatch.com is a focused resource for branded drug patent records and deadlines. Search for Xolair there to view the specific patent entries and their associated expiration/status details. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/xolair